low dose glp 1 agonist GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Microdosed GLP-1 (Semaglutide)

Semaglutide drugs have been shown to increase the risk of eye strokes that cause vision loss

Nonetheless, research focusing on their safety during pregnancy is scarce, with existing studies primarily addressing metabolic effects rather than gestational safety.224 Given that GLP-1/GIP dual agonists modulate multiple metabolic pathways, further research is necessary to elucidate their potential impact on fetal development.227 Additionally, safety assessments of GLP-1RAs and GLP-1/GIP dual agonists in non-pregnant women have identified common adverse reactions, including gastrointestinal discomfort and anorexia

GLP-1 and GIP control blood glucose levels by stimulating insulin secretion by pancreatic -cells while inhibiting glucagon secretion, increasing pancreatic -cell proliferation, and decreasing their apoptosis [3,4,5,6,7,8]

The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: Recent findings and new perspectives

PMID: 36977934